Navigation Links
Currently approved drugs found effective in laboratory mice against bioterror threats
Date:4/11/2013

In the most extensive screen of its kind, Texas Biomed scientists in San Antonio have demonstrated the feasibility of repurposing already-approved drugs for use against highly pathogenic bacteria and viruses. The pathogens included emerging diseases and potential bioterror threats ranging from anthrax to the Marburg and Ebola viruses.

In testing a library of 1,012 Food and Drug Administration-approved drugs, commonly used for treatment of every-day ailments like diabetes and high blood pressure, the scientists found that ten were active against two or more bacteria and that 24 were active against two or more viruses.

Two drugs were found to be the most potent compounds in protecting mice against anthrax while one drug, chloroquine, once used to treat malaria, protected mice against Ebola virus, said Robert Davey, Ph.D., a Texas Biomed virologist.

The new study, which included authors Jean Patterson, Ph.D., and Ricardo Carrion, Ph.D., both of Texas Biomed, appears in the April 2013 issue of the journal PLOS ONE. Their findings came from a collaborative effort among Texas Biomed, independent research institute SRI International and the U.S. Army Medical Research Institute of Infectious Diseases. It was supported by funds from the Defense Threat Reduction Agency, the Defense Department's agency for countering weapons of mass destruction.

"Repurposing of existing drugs that may have unanticipated activities as potential countermeasures is one way to meet this important goal, since currently approved drugs already have well-established safety and pharmacokinetic profiles in patients, and manufacturing and distribution networks," the authors wrote. "Therefore, approved drugs could rapidly be made available for a new indication in an emergency."

The scientists found a variety of hits against two or more of these bio-threat pathogens, which were validated in secondary tests. As expected, antibiotic compounds were highly active against bacterial agents, but the researchers did not identify any non-antibiotic compounds with broad spectrum antibacterial activity.

Lomefloxacin and erythromycin were found to be the most potent compounds in protecting mice against anthrax. Lomeflaxacin is used to treat bronchitis and urinary tract infections. Erythromycin is used against respiratory tract infections.

The most noteworthy antiviral compound identified was chloroquine which disrupted virus entry and replication in cells of two or more viruses in vitro and protected mice against Ebolavirus.

Due to the demanding complexity of working with these agents under laboratory conditions as well as the fact that human drug clinical trials cannot be ethically conducted for any of these agents, conventional drug discovery and development approaches are particularly challenging. For these agents, the FDA must evaluate the efficacy of drugs on the basis of their activities in appropriate animal models, under agency guidance. Thus, drug-repurposing offers many advantages, particularly given the fact that human safety studies have already been conducted.

Members of the Texas Biomed team are presently pursuing whether the other drugs could be equally useful for treatment of these viruses.

"It would be important to determine if a combination of drugs could be more potent than each individual drug," Davey said. "Such synergy, when seen, usually means you can lower the dose of each drug and still have a big impact on the disease while minimizing bad side effects. Such work could prove useful as an easy frontline defense against these viruses."


'/>"/>

Contact: Joseph Carey
jcarey@txbiomed.org
210-258-9437
Texas Biomedical Research Institute
Source:Eurekalert

Related biology technology :

1. iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
2. Tri-Valley Dentist Dr. Endre Selmeczy Currently Features Oral Sedation Dentistry
3. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
4. Indoor Air Quality Professionals Provide New Expert Witness Services To Help Mold Victims Get Mold Claims Approved and Win in Court, AGCEnvironmental Explains How
5. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
6. Recently FDA-Approved Full Neck Treatment for Sagging Skin Now Available at Maryland Laser Skin and Vein Institute
7. Pinnaclife Animal Health Features Seal N Heal Wound Shield in New Veterinary Dermatologist Tested and Approved Product Line!
8. K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court
9. K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court
10. SpermCheck® Fertility, the Only FDA Approved At-Home Screening Test for Men to Determine Normal or Low Sperm Count, Now Available to Couples Planning or Struggling to Conceive
11. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
Breaking Biology News(10 mins):